Immunotherapy Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, UK, China, Japan - Size and Forecast 2024-2028

Published: Nov 2023 Pages: 163 SKU: IRTNTR76823

Immunotherapy Drugs Market Forecast 2024-2028

The Global Immunotherapy Drugs Market size is estimated to grow by USD 111.35 billion at a CAGR of 11.31% between 2023 and 2028. The increasing prevalence of cancer, driven by factors such as aging populations and lifestyle changes, is leading to a greater demand for cancer treatments and therapies. Growing investments in pharmaceutical technology, such as advancements in drug delivery systems and personalized medicine, are driving innovation in the industry and creating new opportunities for growth. Increasing awareness in patients, fueled by initiatives from healthcare organizations and advocacy groups, is leading to earlier detection and treatment of diseases, further driving market growth.

What will be the Size of the Immunotherapy Drugs Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation by End-user, Type and Geography Analysis

By End-user 

The hospitals segment is estimated to witness significant growth during the forecast period. This segment plays an important role in the provision of health care services. Hospitals are the first point of entry for diagnosing, treating, and managing a wide range of diseases. In addition, they provide access to specialists and cutting-edge medical facilities. Furthermore, with the growing acceptance of immunotherapy as an innovative treatment, hospitals have become an essential part of the global market.

Get a glance at the market contribution of various segments Download PDF Sample

The hospitals segment was the largest segment and was valued at USD 56.54 billion in 2018. Moreover,  these work by stimulating an individual's immune system to recognize and kill cancer cells, providing a more targeted and potentially more successful treatment. In addition, hospitals are leading the way in adding this to their treatment plans, making sure patients get the best care possible. Furthermore, they support clinical trials, research, and development efforts which is fuelling the growth of this segment which in turn drives the immunotherapy drug market growth.

By Type 

The presence of the monoclonal antibodies segment has fuelled the growth of the global market. In addition, these antibodies, which are created in laboratories, are designed to bind to and target specific proteins that are present in cancer cells and immune cells. In addition, this selective approach has enabled them to be highly effective in the treatment of a variety of cancers and autoimmune conditions. Furthermore, the monoclonal antibody drug development and approval have seen a dramatic increase in recent years, reflecting the growing prevalence and efficacy of this therapy. Hence, such factors are fuelling the growth of this segment which in turn will drive the market during the forecast period.

By Region

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Some of the main factors that are fuelling the growth of the market in North America include the increasing prevalence of various types of diseases and allergies such as cancer and tuberculosis in the region. In addition, food allergies contribute to a high share of the investments in the immunotherapy market in the region. For example, according to 2021 data from Food Allergy Research and Education (FARE), 32 million people in the US suffer from food allergies. Each year, 200,000 people in the US require emergency medical care due to food allergies. Furthermore, besides allergies, cancer contributes to a large part of the investment of research. Hence, such factors are driving the market in North America during the forecast period.

Buy Full Report Now

Market Dynamics and Customer Landscape

In recent years, significant immunotherapy advancements have reshaped cancer treatment paradigms, with promising results emerging from ongoing clinical trials. While treatment efficacy is a primary focus, managing side effects remains a crucial consideration in optimizing patient outcomes. Moreover, navigating regulatory approvals and addressing market competition are essential for ensuring the widespread availability and affordability of these therapies. Ensuring equitable patient access to innovative treatments is paramount, facilitating broader adoption and improving overall cancer care. 

Key Market Driver

There is a significant expansion of the global market due to the prevalence of cancer, which has become a major contributor to global mortality. Moreover, the number of cancer-related deaths is increasing rapidly. The global market for immunotherapy is also gaining popularity due to the numerous benefits it offers compared to conventional treatments like chemotherapy or radiotherapy. This includes the use of monoclonal antibodies, biosimilars, personalized medicines, and nanoparticles, which can lead to life line curves and improved patient outcomes. Studies have shown that immunotherapies are more effective, yield better patient outcomes, and result in fewer adverse reactions. These factors are contributing positively to the market's growth.

Significant Market Trends

A key factor shaping the market is the emerging drug development techniques. There are significant advances in immunotherapy drug development which are helping pharmaceutical companies to develop more efficient immunotherapies for the treatment of various diseases. For example, SPIRE immunotherapy is one of the most advanced technologies to treat diseases and is currently being used by various pharmaceutical companies.

Moreover, it uses the MicronJet system and helps in maximizing the immune response of the drug. In addition, the popularity of this technology has been growing due to its ease of use and compatibility. Furthermore, this technology is designed to treat various diseases like allergies, such as cat allergy (Cat-SPIRE), HDM allergy (HDM-SPIRE), grass pollen allergy (Grass-SPIRE), and ragweed pollen allergy (Ragweed-SPIRE). Hence, such factors are driving the market during the forecast period.

Major Challenges

The high cost associated with immunotherapy drugs is one of the key challenges hindering the market. One of the major impediments to the availability and affordability of these is their high cost of developing, manufacturing, and marketing. In addition, the main reason is that immunotherapy drugs require extensive clinical research and development, costly manufacturing procedures, and rigorous regulatory approval, all of which contribute to their higher prices.

Moreover, the complexity of immunotherapy medications and their tailored treatment regimen further increase the overall expense. For example, CAR-T cell therapies necessitate the extraction, alteration, and re-fusion of the patient's own immune system, thus adding to the already considerable costs. Hence, such factors are negatively impacting the market which in turn hinders the market growth during the forecast period.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Market Customer Landscape

Key Immunotherapy Drugs Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

AbbVie Inc: The company offers Actonel, Acular, Alloderm and others.

  • Amgen Inc.
  • AstraZeneca Plc
  • Bayer AG
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Co.
  • Celldex Therapeutics Inc.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Immatics NV
  • Incyte Corp.
  • Johnson and Johnson
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • ElevateBio
  • Genmab AS

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Analyst Overview

The market experiences growth spurred by advancements in cancer immunotherapy, addressing chronic diseases like diabetes. Companies like Biomunex Pharmaceuticals pioneer immunotherapy drug candidates, especially for hematological malignancies. Innovations include CAR T-cell therapy and therapeutic monoclonal antibodies, such as Dupixent for plaque psoriasis. Challenges persist, including high attrition rates and the high cost of immunotherapy treatment, motivating Vir Biotechnology and others to develop biosimilar drugs and targeted therapies. With ongoing developments in mRNA-based vaccines and anti-cancer drug prices, the market sees a surge in new product developments aimed at combating various oncology indications and lifestyle disorders.

Furthermore, the market witnesses transformative advances, addressing diverse ailments from cancer to autoimmune diseases like rheumatoid arthritis and Crohn’s disease. Breakthroughs include BiXAR technology and targeted therapies like anti-PD-1 therapy for urothelial carcinoma. Monoclonal antibody treatments, such as Dupixent for prurigo nodularis, redefine care standards. Imugene leads in cancer therapies, targeting lung cancer and melanoma. Challenges persist, from the product development cycle to combating newly diagnosed cancer cases. However, advancements like HIV mRNA-based vaccines and TCRs offer promising avenues. With a focus on cutting-edge treatments and tackling various cancer types, the market promises continued evolution and innovation.

Additionally, the market pioneers cancer immunotherapies like targeted therapy and advanced immunotherapies for various cancers, including cervical cancer treatment. With breakthrough drugs like Dupixent and Olumiant, it also tackles autoimmune and inflammatory diseases. This burgeoning market addresses kidney failure and heart diseases through innovative immunomodulators. From lymphoma to non-small cell lung cancer, immunotherapy revolutionizes cancer treatment, offering hope for patients worldwide.

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

  •  End-user Outlook
    • Hospitals
    • Clinics
    • Others
  • Type Outlook
    • Monoclonal antibodies
    • Vaccines
    • Immune checkpoint inhibitors
    • Others
  • Geography Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of the World (ROW)
      • Australia
      • Argentina
      • Brazil

Immunotherapy Drugs Market Scope

Report Coverage

Details

Page number

163

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 11.31%

Market Growth 2024-2028

USD 111.35 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

10.24

Regional analysis

North America, Europe, Asia, and the Rest of the World (ROW)

Performing market contribution

North America at 43%

Key countries

US, Germany, UK, China, and Japan

Competitive landscape

 Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks

Key companies profiled

AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, BioNTech SE, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celldex Therapeutics Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Immatics NV, Incyte Corp., Johnson and Johnson, Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceutical Industries Ltd., ElevateBio, and Genmab AS

Market dynamics

Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting of the market between 2024 and 2028
  • Precise estimation of the size of the market size and its contribution to the parent market
  • Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
  • Growth of the market industry across Europe, North America, APAC, South America, and Middle East and Africa
  • Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by End-user
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global immunotherapy drugs market 2018 - 2022
      • Exhibit 18: Historic Market Size – Data Table on global immunotherapy drugs market 2018 - 2022 ($ billion)
    • 4.2 End-user Segment Analysis 2018 - 2022
      • Exhibit 19: Historic Market Size – End-user Segment 2018 - 2022 ($ billion)
    • 4.3 Type Segment Analysis 2018 - 2022
      • Exhibit 20: Historic Market Size – Type Segment 2018 - 2022 ($ billion)
    • 4.4 Geography Segment Analysis 2018 - 2022
      • Exhibit 21: Historic Market Size – Geography Segment 2018 - 2022 ($ billion)
    • 4.5 Country Segment Analysis 2018 - 2022
      • Exhibit 22: Historic Market Size – Country Segment 2018 - 2022 ($ billion)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by End-user

    • 6.1 Market segments
      • Exhibit 30: Chart on End-user - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on End-user - Market share 2023-2028 (%)
    • 6.2 Comparison by End-user
      • Exhibit 32: Chart on Comparison by End-user
      • Exhibit 33: Data Table on Comparison by End-user
    • 6.3 Hospitals - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Hospitals - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 35: Data Table on Hospitals - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 36: Chart on Hospitals - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Hospitals - Year-over-year growth 2023-2028 (%)
    • 6.4 Clinics - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Clinics - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 39: Data Table on Clinics - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 40: Chart on Clinics - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Clinics - Year-over-year growth 2023-2028 (%)
    • 6.5 Others - Market size and forecast 2023-2028
      • Exhibit 42: Chart on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 43: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 44: Chart on Others - Year-over-year growth 2023-2028 (%)
      • Exhibit 45: Data Table on Others - Year-over-year growth 2023-2028 (%)
    • 6.6 Market opportunity by End-user
      • Exhibit 46: Market opportunity by End-user ($ billion)
      • Exhibit 47: Data Table on Market opportunity by End-user ($ billion)

    7 Market Segmentation by Type

    • 7.1 Market segments
      • Exhibit 48: Chart on Type - Market share 2023-2028 (%)
      • Exhibit 49: Data Table on Type - Market share 2023-2028 (%)
    • 7.2 Comparison by Type
      • Exhibit 50: Chart on Comparison by Type
      • Exhibit 51: Data Table on Comparison by Type
    • 7.3 Monoclonal antibodies - Market size and forecast 2023-2028
      • Exhibit 52: Chart on Monoclonal antibodies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 53: Data Table on Monoclonal antibodies - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 54: Chart on Monoclonal antibodies - Year-over-year growth 2023-2028 (%)
      • Exhibit 55: Data Table on Monoclonal antibodies - Year-over-year growth 2023-2028 (%)
    • 7.4 Vaccines - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Vaccines - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 57: Data Table on Vaccines - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 58: Chart on Vaccines - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Vaccines - Year-over-year growth 2023-2028 (%)
    • 7.5 Immune checkpoint inhibitors - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Immune checkpoint inhibitors - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 61: Data Table on Immune checkpoint inhibitors - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 62: Chart on Immune checkpoint inhibitors - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Immune checkpoint inhibitors - Year-over-year growth 2023-2028 (%)
    • 7.6 Others - Market size and forecast 2023-2028
      • Exhibit 64: Chart on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 65: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 66: Chart on Others - Year-over-year growth 2023-2028 (%)
      • Exhibit 67: Data Table on Others - Year-over-year growth 2023-2028 (%)
    • 7.7 Market opportunity by Type
      • Exhibit 68: Market opportunity by Type ($ billion)
      • Exhibit 69: Data Table on Market opportunity by Type ($ billion)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 71: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 72: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 73: Chart on Geographic comparison
      • Exhibit 74: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 75: Chart on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 76: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 77: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 80: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 81: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 84: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 85: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 91: Chart on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 92: Data Table on US - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 93: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 China - Market size and forecast 2023-2028
      • Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.9 Germany - Market size and forecast 2023-2028
      • Exhibit 99: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 100: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 101: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.10 UK - Market size and forecast 2023-2028
      • Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.11 Japan - Market size and forecast 2023-2028
      • Exhibit 107: Chart on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 108: Data Table on Japan - Market size and forecast 2023-2028 ($ billion)
      • Exhibit 109: Chart on Japan - Year-over-year growth 2023-2028 (%)
      • Exhibit 110: Data Table on Japan - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 111: Market opportunity by geography ($ billion)
      • Exhibit 112: Data Tables on Market opportunity by geography ($ billion)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 113: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 115: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 116: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 117: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 118: Matrix on vendor position and classification
            • 12.3 AbbVie Inc.
              • Exhibit 119: AbbVie Inc. - Overview
              • Exhibit 120: AbbVie Inc. - Product / Service
              • Exhibit 121: AbbVie Inc. - Key news
              • Exhibit 122: AbbVie Inc. - Key offerings
            • 12.4 Amgen Inc.
              • Exhibit 123: Amgen Inc. - Overview
              • Exhibit 124: Amgen Inc. - Product / Service
              • Exhibit 125: Amgen Inc. - Key offerings
            • 12.5 AstraZeneca Plc
              • Exhibit 126: AstraZeneca Plc - Overview
              • Exhibit 127: AstraZeneca Plc - Product / Service
              • Exhibit 128: AstraZeneca Plc - Key news
              • Exhibit 129: AstraZeneca Plc - Key offerings
            • 12.6 Bayer AG
              • Exhibit 130: Bayer AG - Overview
              • Exhibit 131: Bayer AG - Business segments
              • Exhibit 132: Bayer AG - Key news
              • Exhibit 133: Bayer AG - Key offerings
              • Exhibit 134: Bayer AG - Segment focus
            • 12.7 BioNTech SE
              • Exhibit 135: BioNTech SE - Overview
              • Exhibit 136: BioNTech SE - Product / Service
              • Exhibit 137: BioNTech SE - Key offerings
            • 12.8 Boehringer Ingelheim International GmbH
              • Exhibit 138: Boehringer Ingelheim International GmbH - Overview
              • Exhibit 139: Boehringer Ingelheim International GmbH - Business segments
              • Exhibit 140: Boehringer Ingelheim International GmbH - Key news
              • Exhibit 141: Boehringer Ingelheim International GmbH - Key offerings
              • Exhibit 142: Boehringer Ingelheim International GmbH - Segment focus
            • 12.9 Bristol Myers Squibb Co.
              • Exhibit 143: Bristol Myers Squibb Co. - Overview
              • Exhibit 144: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 145: Bristol Myers Squibb Co. - Key news
              • Exhibit 146: Bristol Myers Squibb Co. - Key offerings
            • 12.10 F. Hoffmann La Roche Ltd.
              • Exhibit 147: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 148: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 149: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 150: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 151: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.11 Gilead Sciences Inc.
              • Exhibit 152: Gilead Sciences Inc. - Overview
              • Exhibit 153: Gilead Sciences Inc. - Product / Service
              • Exhibit 154: Gilead Sciences Inc. - Key news
              • Exhibit 155: Gilead Sciences Inc. - Key offerings
            • 12.12 GlaxoSmithKline Plc
              • Exhibit 156: GlaxoSmithKline Plc - Overview
              • Exhibit 157: GlaxoSmithKline Plc - Business segments
              • Exhibit 158: GlaxoSmithKline Plc - Key news
              • Exhibit 159: GlaxoSmithKline Plc - Key offerings
              • Exhibit 160: GlaxoSmithKline Plc - Segment focus
            • 12.13 Immatics NV
              • Exhibit 161: Immatics NV - Overview
              • Exhibit 162: Immatics NV - Product / Service
              • Exhibit 163: Immatics NV - Key offerings
            • 12.14 Johnson and Johnson
              • Exhibit 164: Johnson and Johnson - Overview
              • Exhibit 165: Johnson and Johnson - Business segments
              • Exhibit 166: Johnson and Johnson - Key news
              • Exhibit 167: Johnson and Johnson - Key offerings
              • Exhibit 168: Johnson and Johnson - Segment focus
            • 12.15 Novartis AG
              • Exhibit 169: Novartis AG - Overview
              • Exhibit 170: Novartis AG - Business segments
              • Exhibit 171: Novartis AG - Key offerings
              • Exhibit 172: Novartis AG - Segment focus
            • 12.16 Pfizer Inc.
              • Exhibit 173: Pfizer Inc. - Overview
              • Exhibit 174: Pfizer Inc. - Product / Service
              • Exhibit 175: Pfizer Inc. - Key news
              • Exhibit 176: Pfizer Inc. - Key offerings
            • 12.17 Sanofi SA
              • Exhibit 177: Sanofi SA - Overview
              • Exhibit 178: Sanofi SA - Business segments
              • Exhibit 179: Sanofi SA - Key news
              • Exhibit 180: Sanofi SA - Key offerings
              • Exhibit 181: Sanofi SA - Segment focus

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 182: Inclusions checklist
                • Exhibit 183: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 184: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 185: Research methodology
                • Exhibit 186: Validation techniques employed for market sizing
                • Exhibit 187: Information sources
              • 13.5 List of abbreviations
                • Exhibit 188: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              immunotherapy drugs market market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis